Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

XENT - Intersect ENT Inc


Previous close
28.24
0   0%

Share volume: 0
Last Updated: Thu 12 May 2022 06:00:00 AM CEST
Medicinal and Botanical Manufacturing : -0.90%

PREVIOUS CLOSE
CHG
CHG%

$28.24
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
28%
Profitability 25%
Dept financing 20%
Liquidity 58%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$28.24
P/E Ratio 
0.00
DAY RANGE
$28.23 - $28.25
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
33.814 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Thomas West
Region: US
Website: www.intersectent.com
Employees: 406
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Medicinal and Botanical Manufacturing
Sector: Manufacturing

Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.

Recent news